Sciele Pharma Inc. (SCRX) is in the Pharma Industry

• Sort by
• View Related Content by Tag

• Sciele Pharma Inc. Q2 2008 Earnings Call Transcript

  Sciele Pharma Inc. SCRX Q2 2008 Earnings Call

  Earnings calls 2008-07-30

  Tags: Call Transcript, Earnings, Seeking Alpha, Sciele Pharma Inc., Financial Accounting, Finance

• Sciele Pharma, Inc. Q1 2008 Earnings Call Transcript

  Sciele Pharma, Inc. Q1 2008 Earnings Call Transcript

  Earnings calls 2008-04-30

  Tags: Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance, Sciele Pharma Inc.

• Sciele Pharma Inc. Q4 2007 Earnings Call Transcript

  Sciele Pharma Inc. Q4 2007 Earnings Call Transcript

  Earnings calls 2008-03-07

  Tags: Sciele Pharma Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Sciele Pharma Q3 2007 Earnings Call Transcript

  Sciele Pharma Q3 2007 Earnings Call Transcript

  Earnings calls 2007-10-30

  Tags: Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance, Sciele Pharma Inc.

Additional Resources

• Sciele Pharma, Inc. Reports Results for the Second Quarter of 2008

  ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX): Second quarter 2008 financial results include: * Pro forma net revenues, a non-GAAP measure, were $111.3 million, excluding $8.1 million in charges related to Sular returns (see note a to the financial statements accompanying this release), an increase of 17%...

  Articles 2008-07-30

• BellwetherReport.com Analyst Report on SINA, BIDU, SCRX and KLAC

  BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...

  Articles 2008-07-28

• Mylan Launches First Generic Version of Antihypertensive Sular® ER in the United States

  PITTSBURGH, July 28 /PRNewswire-FirstCall/ -- Mylan Inc. today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received final approval from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for Nisoldipine Extended-release ER Tablets, 20 mg, 30 mg and 40 mg. ...

  Articles 2008-07-28

• Sciele Pharma Completes Phase III Safety Trial for Glycopyrrolate Liquid, a Treatment for Chronic, Moderate-to-Severe Drooling in Pediatric Patients

  ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has completed its phase III safety trial utilizing a liquid formulation of glycopyrrolate to treat chronic, moderate-to-severe drooling in pediatric patients. This condition often results from cerebral palsy as well as from other neurological disorders. This trial...

  Articles 2008-07-08

• Sciele Pharma Signs Agreement with Addrenex Pharmaceuticals To Develop and Market ADX415 for the Treatment of Hypertension

  ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has signed an exclusive agreement with Addrenex Pharmaceuticals, Inc. to develop and market ADX415, a novel patented, centrally-acting alpha adrenergic receptor agonist, specific to Alpha-2 receptors, for the treatment of hypertension and other potential indications. Under the...

  Articles 2008-07-01

• Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications

  DURHAM, N.C., July 1 /PRNewswire/ -- Two years after Addrenex Pharmaceuticals set it sights on building a new class of drugs to regulate "adrenergic excess," the small Durham company has signed its second major deal with Sciele Pharma, this time to co-develop a new compound for...

  Articles 2008-07-01

• FDA Approves PrandiMet™, a Replaglinide and Metformin Fixed-Dose Combination Tablet for Treatment of Type 2 Diabetes

  ATLANTA & PRINCETON, N.J. -- Sciele Pharma, Inc. (NASDAQ:SCRX) and Novo Nordisk Inc. today announced that the U.S. Food and Drug Administration FDA approved PrandiMet[TM] repaglinide and metformin HCl tablets, the first and only fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin([R])) and insulin...

  Articles 2008-06-24

• SupplyScape Selected by Sciele Pharma for Transaction and Product Security

  SupplyScape helps pharmaceutical company improve product security, expand supply chain visibility and maintain focus on patient safety WOBURN, Mass. -- SupplyScape Corporation, the leading provider of software to secure the safety and value of the pharmaceutical supply chain, today announced that Sciele[R] Pharma, Inc. has...

  Articles 2008-06-17

• Mergent, Inc. Announces Quarterly Rebalancing of HealthShares™ Indexes

  NEW YORK, June 17 /PRNewswire/ -- Mergent, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange Traded Funds, today announced the quarterly rebalancing of the Indexes. The following securities will be added and deleted in the Indexes effective before...

  Articles 2008-06-17

• Zacks Bull and Bear of the Day Highlights: Sciele Pharmaceuticals, Avnet, Berkshire Hathaway, Eli Lilly and Anglo American

  CHICAGO -- Zacks Equity Research highlights Sciele Pharmaceuticals (Nasdaq: SCRX) as the Bull of the Day and Avnet, Inc. (NYSE: AVT) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Berkshire Hathaway (NYSE: BRK.A), Eli Lilly & Co. (NYSE: LLY) and Anglo...

  Articles 2008-06-12

• Sciele Pharma to Present at the Goldman Sachs 29th Annual Global Healthcare Conference

  ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, today announced that Ed Schutter, President and Chief Operating Officer, will make a presentation at the Goldman Sachs 29th Annual Global Healthcare Conference at the Ritz-Carlton Laguna Niguel in Dana Point, California on Wednesday, June 11, at...

  Articles 2008-06-05

• Sciele Pharma Announces That Addrenex Has Completed Enrollment of Pivotal Phase III Trial for Clonicel for ADHD

  ATLANTA -- Sciele Pharma, Inc. (NASDAQ: SCRX), a specialty pharmaceutical company, today announced that Addrenex Pharmaceuticals has completed patient enrollment of its first Phase III clinical trial in the U.S. for Clonicel to treat attention deficit and hyperactivity disorder ADHD in children. Addrenex is also continuing to enroll patients in...

  Articles 2008-06-03

• Sciele Pharma to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference

  ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, today announced that Ed Schutter, President and Chief Operating Officer, will make a presentation at the UBS Global Specialty and Generic Pharmaceuticals Conference at the Waldorf Hilton Hotel in London on Thursday, May 29, 2008, at 11:00 a.m. local time...

  Articles 2008-05-23

• Sciele Pharma to Present at Bank of America Health Care Conference

  ATLANTA -- Sciele Pharma, Inc. (NASDAQ: SCRX), a specialty pharmaceutical company, today announced that Ed Schutter, President and Chief Operating Officer, will make a presentation at the Bank of America Health Care Conference at the Four Seasons in Las Vegas, on Tuesday, May 13, 2008, at 12:40 p.m. Pacific Time...

  Articles 2008-05-08

• Sciele Pharma, Inc. Reports Results for the First Quarter of 2008

  ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX): First quarter 2008 financial results include: * Revenues were $100.4 million, an increase of 22% over the first quarter of 2007. * Diluted earnings per share were $0.32 (inclusive of a non-cash impairment charge totaling $0.03 per share)...

  Articles 2008-04-30

• Sciele Pharma, Inc. Adopts $100 Million Share Repurchase Program

  Approves Redemption of Poison Pill ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, today announced that its Board of Directors has adopted a new share repurchase program, authorizing the repurchase of up to $100 million of its outstanding shares of common stock over the next 12...

  Articles 2008-04-28